Publications
213
Citations
3,340
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1997
Wei Tang publishes broadly across clinical medicine, with a concentration on cancer diagnosis and treatment—especially lung cancer—including work on imaging-based prognosis, molecular and genetic markers, and immunotherapy. The publication record also spans related areas such as blood cancers (lymphoma), asthma treatment, and other clinical topics, often through multi-center studies and analyses combining genetic and imaging data.
Publication activity has grown over the past decade, rising from a few papers per year to a peak of 38 in 2025, with an average of about 17 per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Current awards run through June 2030 — about 4 years of funding on record from today. Awards are often renewed, so this is what is currently public, not a forecast.
CAREER: Compositional Learning and Understanding of the Physical World
Collaborative Research: Deciphering Nutrient Sources and Microbial Processes Fueling the Great Atlantic Sargassum Belt
Collaborative Research: Statistical Foundations for Scalable and Robust Data Valuation
CCSS: Modeling and Learning Space-time Structures for Real-time Environment Perception
Statistical Learning and Inference for Network Data with Positive and Negative Edges
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~10 · 2% small-team papers (≤3 authors) · across 97 venues
- Lipidomic signatures as predictive biomarkers for early-onset lung cancer: Identification and development of a risk prediction model
Journal of Advanced Research · 2025
- Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients
Signal Transduction and Targeted Therapy · 2025
- Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition
BioScience Trends · 2025
- Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)
Signal Transduction and Targeted Therapy · 2025
- NIR-II imaging-based detection of early changes in lower limb perfusion in type 2 diabetes patients without peripheral artery disease
Diabetes Research and Clinical Practice · 2025
- Machine learning‑based radiomics models for the prediction of metachronous liver metastases in patients with colorectal cancer: A multimodal study
Oncology Letters · 2025
- Glycolysis-inhibiting tumor cell-derived microparticles to enhance immunogenic cell death for synergistic cancer immunotherapy
Biomaterials · 2025
- Case Report: Management of intracranial hypertension in acute-on-chronic liver failure: a case of fulminant cerebral edema and acute-onset severe hyperammonemia in a patient with cirrhosis
Frontiers in Gastroenterology · 2025
- The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer
Frontiers in Oncology · 2025
- Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study
The Journal of Allergy and Clinical Immunology In Practice · 2025
- Causal association between dietary factors and chronic kidney disease: a Mendelian randomisation study
British Journal Of Nutrition · 2025
- Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment
HemaSphere · 2025
- Injectable heavy-atom-free photosensitizer platform for near-infrared activated synergistic photoimmunotherapy
Journal of Colloid and Interface Science · 2025
- Kimura Disease With Eosinophilic Granulomatosis With Polyangiitis Successfully Treated by Mepolizumab
Clinical Case Reports · 2025
- Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)
Blood · 2025
- PubMed×8
- Research Square×6
- Frontiers in Oncology×5
- Blood×5
- eLife×4
- J. Wang
Medicine · University of Michigan
- Claudia I. Henschke
Medicine · University of Michigan
- Manny Coker‐Schwimmer
Medicine · The Ohio State University
- Jian Cui
Medicine · Indiana University
- Robert E. Merritt
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile